EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu und 18 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114327 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Alexander Mm Eggermont und 29 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximilians University, Munich, Germany; Princess Máxima Center …. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Neoplasm Staging, Skin Neoplasms. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntibodies, Monoclonal, HumanizedNeoplasm StagingSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleChemotherapy, AdjuvantMiddle AgedDouble-Blind MethodFollow-Up StudiesAgedB7-H1 AntigenAdultTime Factors

Stichwörter der Autor:innen

Adjuvant treatmentAnti-PD1Anti-PDL1Clinical trialImmune checkpoint inhibitorsImmunotherapyMelanomaPembrolizumabPhase 3

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 Antigen

Autor:innen und Institutionen

  • Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximilians University, Munich, Germany; Princess Máxima Center and University Medical Center Utrecht, Utrecht, the Netherlands. Elect…
  • EORTC Headquarters, Brussels, Belgium.
  • Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • University of Perugia, Santa Maria Misericordia Hospital, Perugia, Italy.
  • Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, Australia.
  • Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.

Zitieren

APA

Eggermont, A. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M., Di Giacomo, A. M., …, & Robert, C. (2024). Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114327

Vancouver

Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114327

BibTeX
@article{Eggermont2024,
  author = {Eggermont, Alexander Mm and Kicinski, Michal and Blank, Christian U and Mandala, Mario and Long, Georgina V and Atkinson, Victoria and Dalle, Stéphane and Haydon, Andrew and Meshcheryakov, Andrey and Khattak, Adnan and Carlino, Matteo S and Sandhu, Shahneen and Larkin, James and Puig, Susana and Ascierto, Paolo A and Rutkowski, Piotr and Schadendorf, Dirk and Boers-Sonderen, Marye and Di Giacomo, Anna Maria and van den Eertwegh, Alfonsus Jm and Grob, Jean-Jacques and Gutzmer, Ralf and Jamal, Rahima and van Akkooi, Alexander C J and Lorigan, Paul and Grebennik, Dmitri and Kreplere, Clemens and Marreaud, Sandrine and Suciu, Stefan and Robert, Caroline},
  title = {Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114327}
}
Kostenlos starten →